
SpectronRx becomes second GMP site for Reyobiq supply
Plus Therapeutics began manufacturing activities and technology transfer with SpectronRx to support late-stage clinical supply of Reyobiq, its rhenium-186 radiopharmaceutical candidate for CNS cancers.








